20449 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Stable emulsion formulations
#302NOVEL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE II DIABETES AND HYPERTENSION
#303Multifunctional supramolecular hydrogels as biomaterials
#304Neuroprotection with Beta-Lactam Compounds
#3054-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors
#306Medication spray formulation
#307Antimicrobial composition
#308Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration
#309Compound antibacterial drugs comprising n-acetyl-d-glucosamine
#310Preparation for gastric buoyant sustained drug release dosage form
#311Identification and application of antibiotic synergy
#312Method and composition for treating otitis media
#313Nanoparticulate and controlled release compositions comprising a cephalosporin
#314Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
#315DRUG DELIVERY SYSTEM
#316Uses of rifamycins
#317Use of antibiotics as vaccine adjuvants
#318POLYPEPTIDES WITH THE CAPACITY TO ENTRAP DRUGS AND RELEASE THEM IN A CONTROLLED WAY
#319BETA-LACTAM ANTIBIOTIC-CONTAINING TABLET AND PRODUCTION THEREOF
#320Wound healing compound
#321Methods and compositions for applying pharmacologic agents to the ear
#322Neurotherapeutic treatment for sexual dysfunction
#323Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
#324Methods of reducing minimal inhibitory concentration of antibiotics and compositions resulting therefrom
#325Effervescent powders for inhalation
#326Oral pharmaceutical suspension of Cefdinir crystal
#327Process for the preparation of dispersible tablets of cephalexin
#328Combinations of DnaK inhibitors with known antibacterial agents
#329Methods and compositions for increasing the efficacy of biologically-active ingredients
#330Glutamate agents in the treatment of mental disorders
#331Methods and composition for the treatment of cystic fibrosis and related illnesses
#332Bioavailability enhancing activity of carum carvi extracts and fractions thereof
#333Pharmaceutical composition
#334Medicinal composition for treating infection with drug-resistant staphylococcus aureus
#335Extended release formulation of beta-lactam antibiotics
#336Control of biofilm with a biofilm inhibitor
#337Colloidal solid lipid vehicle for pharmaceutical use
#338Bioavailability/bioefficacy enhancing activity of and extracts and fractions thereof
#339Oral pharmaceutical suspension of Cefdinir crystal
#340Dalfopristine/quinupristine combinations with cefpirome
#341Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same
#342Compositions for treating cystic fibrosis
#343Dispersible tablet for oral administration
#344Antibiotic product formulation
#345Probiotic, lactic acid-producing bacteria and uses thereof
#346Pharmaceutical composition for topical application
#347Use of an inhibitor of cathepsin-S or -B to treat or prevent chronic obstructive pulmonary disease
#348Sustained release of antiinfectives
#349Methods and compositions for the dietary management of autoimmune disorders
#350Use of an inhibitor of cathepsin-S-or-B to treat or prevent chronic obstructive pulmonary disease
#351Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
#352Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
#353Benzotriazepnes as gastrin and cholecystokinin receptor ligands
#354Tablet for pulsed delivery
#355Method for reducing radiation-induced normal tissue damage
#356Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders
#357Cross-linked glycopeptide—cephalosporin antibiotics
#358Compositions for treating biofilm
#359Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic
#360Novel substituted alkane compounds and uses thereof
#361Glucocorticoid blocking agents for increasing blood-brain barrier permeability stan-261con
#362Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
#363Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
#364Treatment of Francisella infection with an IFN-gamma inducer and a chemotherapeutic agent
#365Pharmaceutical compositions
#366Method of treating middle ear infections
#367Compositions for and methods of treating and preventing sirs/sepsis
#368Methods of treatment of chronic immune disease
#369Pharmaceutical composition for controlled release of a beta-lactam antibiotic
#370Antibiotic product, use and formulation thereof
#371Flashmelt oral dosage formulation
#372Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth
#373IL-15 agonist drug combinations for immune therapy